Beta secretase inhibitors to treat Alzheimer's disease

With each new amyloid-targeting treatment for Alzheimer’s disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-? peptide (A?) produce inflammation in the brain in some patients. Gamma secretase inhibitors tend to produce adverse effects by interacting with Notch, an important pathway for cellular signaling. Beta secretase 1 (BACE1) inhibitors are a new and promising target for Alzheimer’s disease. Inhibiting BACE1 will limit the production of A? which, in turn, should reduce the production of neurotoxic fibrils and plaques, scientists say.



from Latest Science News -- ScienceDaily http://ift.tt/1an8NWJ via Karis World